Medical Pharma, Inc. (OTCQB:TRGM) today announced that Dr. Thomas
Wenkart, Chief Executive and Chairman at Macquarie Health Corporation,
has joined the company's board of directors.
A nationally respected expert in healthcare, medical and hospital
administration in Australia, Dr. Wenkart established Macquarie Health
Corporation in Sydney, Australia, in 1976. His organization owns and
operates eleven private hospitals in Australia, and is one of the
nation's leading providers of healthcare services.
Dr. Wenkart is a graduate of the Sydney University School of Medicine.
In 1976, he established the Health Care Research Institute and the
Wenkart Foundation, which supports the Arts and Health Sciences with the
credo of "community benefits in the shortest possible time." In 2007,
the Wenkart Foundation established the Wenkart Chair of Endothelium
Medicine at Sydney University and the Centenary Institute. Dr. Wenkart
has a unique understanding and interest in medical computing, electronic
health records, biomedical technology, and videodermoscopy systems. In
2003, he acquired Derma Medical Systems in Austria.
"We are very pleased to have Dr. Wenkart join our company. He brings a
great deal of healthcare and business experience to our board," said Dr.
William Shell, Chief Executive Officer and Chief Science Officer at
Targete Medical Pharma. "His expertise in operations and management
systems will help the continued growth and execution of strategic
initiatives of our company in the United States and abroad."
Twitter: @tmedpharmaFacebook: www.facebook.com/targetedmedicalpharma
About Targeted Medical Pharma, Inc.
Medical Pharma, Inc. is a Los Angeles-based biotechnology company
that develops medical
foods for the treatment of chronic disease, including pain
syndromes, peripheral neuropathy, hypertension, obesity, sleep and
cognitive disorders. The company also develops a line of dietary
supplements designed to support health and wellness. The company
manufactures 10 proprietary medical foods, and recently launched its
first dietary supplement, Clearwayz™.
The products are sold directly to physicians and pharmacies in the U.S.
The company also is developing nutrient-based systems for oral
stimulation of progenitor stem cells that differentiate into neurons,
red blood cells and pituitary hormones including IGF-I.
This press release may contain forward-looking statements related to
Targeted Medical Pharma's business strategy, outlook, objectives, plans,
intentions or goals. The words "may," "will," "should," "plans,"
"explores," "expects," "anticipates," "continue," "estimate," "project,"
"intend," and similar expressions identify forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of
1995, but their absence does not mean that the statement is not forward
looking. These statements are not guarantees of future performance and
are subject to certain risks, uncertainties and assumptions that are
difficult to predict. Actual results could differ materially. Targeted
Medical Pharma expressly disclaims any obligation or undertaking to
update or revise any forward-looking statement contained herein to
reflect any change in the company's expectations with regard thereto or
any change in events, conditions or circumstances upon which any
statement is based.
[ Back To NFVZone's Homepage ]